Authors
Latest:
Dr. Horn on the Role of Mobocertinib in NSCLCLeora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non–small cell lung cancer.
Latest:
Dr. Kohman Discusses Importance of Lung Cancer ScreeningLeslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate University Hospital, Upstate Cancer Center, discusses the importance of lung cancer screening.
Latest:
Future Directions in the Treatment of Recurrent or Metastatic Cervical CancerThe panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.
Latest:
Leading City of Hope Hematologists Appointed to New PositionsLarry Kwak, MD, PhD, has been appointed the deputy director of City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.
Latest:
Dr. Roberts on the Prevalence of Liver CancerLewis R. Roberts, MB, ChB, PhD, professor of Medicine, Mayo Clinic, discusses the prevalence of hepatocellular carcinoma (HCC).
Latest:
Are Surgery and Chemotherapy Sufficient to Treat Locally Advanced Bladder Cancer?The challenge of pelvic failure following contemporary cystectomy has been engaged and the clinical trials to pursue the amelioration of this problem have commenced.
Latest:
Internal Investigations May be Open to Court and Government Agency ScrutinyGiven a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.
Latest:
Why We�re Not Reaching Women With Metastatic Breast Cancer and How We Can Change ThatBreast Cancer Network of Strength is always looking for different ways to meet the needs of women with breast cancer.
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
MIPS Transition: CMS Cushions the Leap to ValueThe final rule for the Quality Payment Program authorized by the Medicare Access and CHIP Reauthorization Act of 2015 was recently released.
Latest:
Dr. Duska on Primary Debulking Surgery in Ovarian CancerLinda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.
Latest:
Our Move to an EHRThe initial capital outlay for transitioning to an EHR is not small. In fact, cost is one of the main reasons practices have been slow to adopt EHRs.
Latest:
Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBCLinda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.
Latest:
Dr. Fraizer Discusses the MaGIC ConsortiumLindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.
Latest:
Helping Patients With Cancer Address Fertility ChallengesOncofertility is the specialty dealing with the clinical care of patients who will lose their fertility due to cancer treatment.
Latest:
Dr. West on Pain Management for Endometrial CancerLindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.
Latest:
Dr Carey on Response-Guided Therapy in HER2+ Breast CancerLisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.
Latest:
Dr. Newman on Advances in Axillary Surgery in Breast CancerLisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.
Latest:
CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 RelapseCD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.
Latest:
Nurse-Driven Website Empowers Nurses to Improve Patient CareImproving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.
Latest:
Lisa Butterfield on SITC Immune Biomarkers Task ForceLisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.
Latest:
Dr. Carey on the Clinical Implications of the FeDeriCa trial in HER2+ Breast CancerLisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.
Latest:
Dr. Roth on Treating AYA Patients With Hodgkin LymphomaLisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.
Latest:
Potential Role of Immunotherapy in the Treatment of Patients With SarcomaLisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.
Latest:
5-FU Dose Optimization: Another Step Towards Personalizing Cancer CareAccording to the Centers for Disease Control and Prevention, colorectal cancer is the second leading cancer killer in the United States, affecting both men and women.
Latest:
Dr Barroilhet on the Role of PARP Inhibitors in BRCA+ and HRD Ovarian CancerLisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.
